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 INTRODUCTION 
 One hundred years after its scientific description, American 
Trypanosomiasis or Chagas disease (CD) remains the largest 
parasitic burden in Latin America. The epidemiology of CD 
has changed because of the migratory trends at the beginning 
of the 21st century, and CD is emerging as a global infectious 
disease. 1, 2 Despite successful control measures in some regions 
of Latin America based on the prevention of the vectorial and 
transfusional transmission of the etiological agent (the proto-
zoan parasite  Trypanosoma cruzi ), 3 many challenges remain. 
First, there are limitations of currently available specific treat-
ment, benznidazole (LAFEPE, Pernambuco, Brasil; ex-Roche ) 
and nifurtimox (Bayer, Leverkusen, Alemania), because of 
limited efficacy in the chronic stage of the disease, which is 
the most prevalent clinical presentation of this condition, 4 and 
common unwanted side effects. Second, there is a lack of bio-
logical markers for the early evaluation of antiparasitic drug 
efficacy and clinical response. 
 The latter aspect is particularly pressing for the management 
of adult patients with chronic disease because of three aspects. 
First, evaluation of the clinical response to specific treatment 
would require years or decades of follow-up. Second, conven-
tional serology responds slowly to parasite elimination, and 
the lag time increases with the duration of the original infec-
tion. 5– 8 Third, in chronic infections, the levels of circulating 
parasites are often at or below the limit of the most sensitive 
direct parasitological methods, such as PCR. 9– 13 
 Moreover, many patients with chronic CD have other health 
conditions, including immunosuppression, which can severely 
complicate the prognosis. Concomitant infections of  T. cruzi 
and human immunodeficiency virus (HIV) are serious and have 
been well-described. Also, advances in other medical fields have 
led to increased use of immunosuppressive treatments for some 
conditions (malignancies and autoimmune diseases), and this 
generally increases the severity of CD clinical presentation. 
 Reactivation of CD in patients with acquired immunodefi-
ciency syndrome (AIDS) is well-documented, and the need for 
treatment and secondary prophylaxis has led to several proto-
cols for management for these dual infections, although cur-
rently there is no general consensus. 14 There is also evidence 
that CD can be reactivated in patients with hemoproliferative 
malignancies, 15 and as reported in one case, comorbidity with 
systemic lupus erythematosus (SLE) can occur. 16 Although, 
to the best of our knowledge, acute reactivation of CD has 
not been documented in autoimmune disorders, the need for 
continuous immunosuppressive treatment generates a risk for 
reactivation or the potential development of severe chronic 
forms of disease in these patients. 17 
 In this report, we describe benznidazole treatment failure 
in a patient with CD and SLE as well as subsequent successful 
treatment with posaconazole. 
 CASE DESCRIPTION 
 A 44-year-old Argentinean female with a 1-year history 
of arthritis and malaise was admitted to the hospital in April 
2007 with fever, asthenia, and edema. The patient had previ-
ously suffered untreated high blood pressure and had been 
diagnosed with  T. cruzi infection 20 years before admission. 
 Epidemiologically, the patient came from the Misiones prov-
ince of northern Argentina, an endemic region for CD, and 
arrived in Spain 5 years before admittance. She never lived in 
a mud house, which is a risk factor for CD, but 25 years before 
admittance, she received a blood transfusion during her first 
delivery. In this case, the infection might have been caused by 
vector-borne transmission and/or by blood infected by  T. cruzi 
that she received 25 years ago in a transfusion. Until April 
2006, she remained asymptomatic, had not been followed-up 
for  T. cruzi infection, and had never received specific treat-
ment. The patient was admitted in our hospital from April 26 
to May 5, 2007. At admission, abnormal laboratory values 
included leucopenia (3.5 × 10 9 /L), low hemoglobin (83 g/L), 
and increased erythrocyte sedimentation rate (90 mm/hour), 
whereas C-reactive protein was normal (1 mg/dL). In addi-
tion, elevated urea (110 mg/dL), and creatinine (3.2 mg/dL) 
were detected. Urine analysis showed cloudy urine with pro-
teinuria (2,165 mg/24 hours), a white cell count of 15–20 per 
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high-power field (HPF), granular casts (1–2/HPF), and many 
erythrocytes. Autoantibody screening showed high titers of 
antinuclear antibodies (1:640) with a homogeneous pattern 
and antibodies against double-stranded DNA (dsDNA) up 
to 200 U/mL (normal range = 0.0–19.9). There were also low 
complement titers of C4 (< 0.07 g/L; normal range = 0.11–0.45), 
C3 (0.262 g/L; normal range = 0.820–1.870), and CH50 (2 U/mL; 
normal range = 34–71). Antiphospholipid antibodies, includ-
ing lupus anticoagulant and anticardiolipin antibodies, were 
negative. 
 Kidney biopsy showed diffuse lupus nephritis class IV-G 
(A) with an activity index of 10/24 and a chronicity index 
of 5/12. A diagnosis of SLE with active lupus nephritis was 
made, and treatment with three pulses of methylprednisolone 
(1 g/day for 3 days followed by prednisone at 1 mg/kg/day 
slowly tapered) was started on April 27, 2007. It was followed 
by monthly intravenous cyclophosphamide (IVC; 750 mg/m 2 
of body surface) for 6 months (from May to October 2007). 
 A control electrocardiogram (EKG) was normal, but 
echocar diography showed a concentric hypertrophy of the left 
ventricle, dilatation of the right atrium, mild tricuspid insuffi-
ciency, and mild pulmonary hypertension, probably caused by 
chronic hypertension. 
 Also at admission (April 2007), the patient was confirmed 
to be positive for  T. cruzi infection using two different sero-
logical enzyme-linked immunosorbent assay (ELISA) tests: 
ELISAr with a ratio of 8.3 (BioELISA Chagas, Biokit S.A., 
Lliçà d’Amunt, Barcelona, Spain with recombinant antigens) 
and ELISAc with a ratio of 153 (an in-house ELISA with 
whole  T. cruzi epimastigotes antigen) 18 ( Table1 ). ELISA by 
Biokit was carried out following the instructions of the manu-
facturer. A cut-off was calculated by adding 0.300 to the mean 
absorbance of the negative control. The results are recorded as 
follows: positive, absorbance ratio sample/cut-off ≥ 1; negative, 
absorbance ratio sample/cut-off < 0.9; equivocal, absorbance 
ratio sample/cut-off ≥ 0.9 but < 1.0. For the ELISAc, the reac-
tion was quantified as units (U) related to a positive serum, 
included in the plates, used as calibrator and arbitrarily set at 
100 U. The cut-off was established at 20 U. 
 In this context, after the initial immunosuppressive treat-
ment, weekly clinical and parasitological (polymerase chain 
reaction [PCR] and thick blood film) follow-ups were made. 
In May 2007, a real-time PCR (RT-PCR) 19 for  T. cruzi was pos-
itive ( Table 1 ), which led to treatment with benznidazole of 5 
mg/kg/day for 60 days starting simultaneously with the IVC 
treatment. The patient showed no clinical symptoms related to 
 T. cruzi, and no significant side effects related to benznidazole 
were detected. 
 After six monthly pulses of IVC, the patient’s symptoms 
improved, and there was complete response of lupus nephritis 
(normalization of the plasma creatinine levels and disappear-
ance of hematuria and proteinuria). Six months after the end 
of benznidazole treatment (February 2008) and before the 
next round of monthly IVC immunosuppressive treatment, a 
RT-PCR test for  T. cruzi was carried out and was again found 
to be positive, although the calculated circulating parasite 
levels were 10–100 times lower than in the pre-benznidazole 
assay ( Table 1 ). Because of the required maintenance of 
immunosuppressive treatment with azathioprine (100 mg/day 
orally), the risk of development of neurological or cardiac 
complications, and the failure of the benznidazole treatment, 
an off-label treatment with posaconazole (Noxafil oral sus-
pension; Schering Plough Corporation, Kenilworth, NJ) was 
suggested on a compassionate basis with the agreement of the 
Spanish Ministry of Health. After informed consent by the 
patient, a 400 mg per 12 hour for 90 days posaconazole treat-
ment was given, starting 45 days before the start of the new 
IVC treatment. Posaconazole was well-tolerated, and  T. cruzi 
blood PCR was consistently negative throughout the follow-
up interval that was 13 months after the start of posaconazole 
treatment (nine consecutive negative PCR tests); immunosup-
pressive treatment was maintained during this time ( Table 1 ). 
After two additional quarterly pulses of IVC and then a switch 
to azathioprine (100 mg/day), the patient presented normal 
renal function and no SLE recurrence in January 2010. It should 
be noted that, despite consistently negative blood PCR tests 
after posaconazole treatment, the levels of anti- T. cruzi circu-
lating antibodies detected by conventional serology remained 
essentially unchanged ( Table 1 ). 
 Other drug therapies concomitant with posaconazole treat-
ment included hydroxychloroquine (200 mg/day), enalapril 
(20 mg/day), atenolol (100 mg/day), omeprazole (20 mg/day), 
and atorvastatin (40 mg/day). Currently, 2 years after initial 
diagnosis, the patient continues with prednisone (2.5 mg/day), 
azathioprine (100 mg/day), hydroxychloroquine (200 mg/day), 
and calcium plus vitamin D. 
 DISCUSSION 
 Benznidazole, a 2-nitroimidazole derivative, and nifurtimox, 
a 5-nitrofuran, are the only drugs currently available for 
specific CD treatment. In newborns, the drugs are well-
tolerated and have an efficacy of ≥ 95%; 20 in acute adult 
infections, the efficacy is also high, but side effects increase 
with age. However, efficacy declines markedly with the dura-
tion of infection. 21 Although several studies have shown that 
 Table 1 
 Serological and parasitological results for  T. cruzi infection after treatment with benznidazole and posaconazole 
 BZD = benznidazole; ELISA = enzyme-linked immunosorbent assay; r = recombinant, c = in house; RT-PCR = real-time polymerase chain reaction; Neg = negative values. 
 *  Posaconazole treatment started on 3/17/08. 
 † The reaction results were quantified as a ratio following the manufacturer’s instructions. Positive values ratio ≥ 1. 
 ‡ The reaction results were quantified as units (U) related to a positive serum used as the calibrator and was arbitrarily set at 100 U. The cut-off was established at 20 U. 
 §  RT-PCR reactions were performed in triplicate for each sample. Ct = cycle threshold (see Piron and others 19 ). Positive values: Ct25 = 10 parasites/mL; Ct35 = 0.1–1.0 parasites/mL. Negative 
values: Ct = 45 (< 0.01 parasites/mL). 
Date
Before BZD After BZD During treatment with posaconazole * After treatment with posaconazole
5/17/07 2/6/08 3/18/08 4/28/08 5/16/08 5/23/08 6/6/08 6/18/08 8/5/08 10/13/08 4/6/09
ELISAr † 8.3 6.7 6.6 6.9 4.4 7.7 7.3 6.7 7.1 7.7 6.2
ELISAc ‡ 153 99 109 114 100 114 102 104 98 118 114
RT-PCR § Ct25 Ct35 Neg Neg Neg Neg Neg Neg Neg Neg Neg
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benznidazole is unable to induce parasitological cures in the 
majority of chronically infected adult patients, 22, 23 there is 
an increasing trend to offer antitrypanosomal treatment to 
infected adults with asymptomatic disease or early cardiomyo-
pathy, because it has been shown in some studies that this drug 
can slow down the progression of cardiac lesions. 24 This could 
be explained by a reduction of the patients’ parasite load and 
the associated inflammatory response at the sites of infection. 
The suboptimal response rates attained with benznidazole and 
nifurtimox in patients with established chronic infections are 
partially explained by the natural resistance of some  T. cruzi 
strains 25 and by the drugs’ inadequate pharmacokinetic prop-
erties. 4 However, the role of the host immunological response 
on the drugs’ activity is not yet fully understood. 
 Currently, specific treatment is universally indicated for 
reactivation in immunosuppressed patients with  T. cruzi infec-
tion, and it might be indicated for preventing reactivation in 
the asymptomatic or indeterminate phase, although no con-
sensus exists for the latter application. Severe fatal cases of 
meningoencephalitis and/or myocarditis have been described 
as caused by reactivation of  T. cruzi infection in immunosup-
pressed patients, although both complications are almost never 
seen in immunocompetent patients with CD. 26 These unusual 
manifestations have also been reported in CD patients with 
immunosuppression because of other causes, such as immu-
nosuppressive treatment post-transplantation. 27, 28 Different 
strategies for control of the reactivation of  T. cruzi infec-
tion in immunosuppressed patients have been proposed. 
Benznidazole is the treatment of choice for reactivated CD 
in HIV-infected patients, 25 whereas for nifurtimox, there is 
much more limited experience. In patients with AIDS, second-
ary prophylaxis (benznidazole three times per week) is recom-
mended, but it is often discontinued when CD4+ lymphocytes 
are above 200 cells/μL. 14 Retreatment is recommended for 
HIV-infected patients who fail to respond or who relapse after 
initial antiparasitic therapy. 29 
 Currently, there is no consensus on the management of 
chronic CD patients that require immunosuppression by cor-
ticosteroids, despite the fact that such treatments are a criti-
cal reactivation risk. Some authors advocate the concomitant 
administration of anti- T. cruzi treatment, even in absence of 
acute CD symptoms (a strategy called primary prophylaxis), 27 
whereas others are more conservative in the absence of clini-
cal trials. Moreover, there is very little experience in patients 
with CD and concomitant autoimmune diseases. Knowing the 
unpredictable and usually long-term evolution of CD manifes-
tations, treatment of immunosuppressed patients who exhibit 
detectable parasitemia seems to be a prudent therapeutic 
conduct. Currently available high-sensitivity methodologies, 
such as serial RT-PCR, allow for the early detection of rising 
circulating  T. cruzi levels before the appearance of clinical 
symptoms of reactivation, which can lead to precocious specific 
treatment to avoid possible subsequent complications. 30– 32 
 New drugs approved for use in humans for other indications, 
such as new antifungal triazole derivatives that are selective 
inhibitors of  T. cruzi ergosterol synthesis (acting at the level of 
C14α sterol demethylase, CYP51), are promising alternatives 
for specific chronic CD treatment; these compounds have high 
anti- T. cruzi efficacy in vitro and in experimental animal mod-
els of both acute and chronic CD, and they are active against 
nifurtimox- and benznidazole-resistant strains of  T. cruzi , even 
in immunosuppressed hosts. 33 The remarkable in vivo anti-
 T. cruzi activities of these compounds are thought to result 
from their potent intrinsic activity against the parasite (minimal 
inhibitory concentrations against intracellular amastigotes in 
vitro in the low nanomolar to subnanomolar range) and spe-
cial pharmacokinetic properties, such as long terminal half-life 
and large volumes of distribution. 34 Among the new triazole 
derivatives, posaconazole—currently registered in the United 
States, the European Union, and Australia for the treatment 
and prophylaxis of invasive fungal infections—is the most 
advanced candidate for a new anti- T. cruzi drug. 
 In our patient, an IVC immunosuppressive treatment was 
indicated for SLE and had satisfactory results, but specific 
treatment of the  T. cruzi infection with benznidazole was 
unable to clear the circulating parasites, as indicated by a 
positive RT-PCR 6 months after antiparasitic treatment. For 
the reasons given above, posaconazole seemed an appropri-
ate drug for treating the established  T. cruzi infection of the 
patient, despite the fact that it is not currently registered as an 
antiparasitic drug. In immunocompetent patients, even serial 
negative  T. cruzi blood PCR tests cannot prove the absence 
of intracellular parasites in the target tissues, but in the pres-
ent case, the fact that parasitemia levels consistently stayed 
below the detection limit of our RT-PCR assay during and 
after posaconazole treatment, despite the maintenance of 
immunosuppressive therapy, strongly suggests a drug-induced 
parasitological cure of the patient. This interpretation is sup-
ported by the results of a recent study in a murine model of 
chronic CD where parasitological cures induced by benznida-
zole treatment were ascertained by the lack of parasitemia 
reactivation induced by cyclophosphamide, which strictly cor-
related with negative  T. cruzi PCR tests in target tissues. 35 
Also in accordance with this conclusion, the patient has not 
shown any sign of clinical CD symptoms during the follow-
up. However, the levels of anti- T. cruzi antibodies detected by 
conventional serology (ELISA) were not significantly modi-
fied by posaconazole treatment ( Table 1 ). Such “dissociation” 
between parasitological and conventional serological tests has 
also been found in previous studies of the response of chronic 
 T. cruzi infections to specific drug treatments. 36 Our results 
showed that posaconazole had superior efficacy when com-
pared with benznidazole in controlling a chronic  T. cruzi infec-
tion compounded by sustained immunosuppression. Finally, 
posaconazole treatment was well-tolerated with no adverse 
events detected during or after 90 days of treatment. 
 Although posaconazole seems to be the best pharmacologi-
cal alternative to benznidazole and nifurtimox for specific CD 
treatment, its current cost is too high for its widespread use in 
endemic countries; however, this limitation could potentially 
be negotiated, and other drugs with the same mechanism of 
action and similar pharmacokinetic profile but lower poten-
tial cost of goods could also enter clinical development for 
this condition in the future (see  http://www.dndi.org/press-
releases/532-eisai-and-dndi-enter-into-a-collaboration.html ). 
 CONCLUSIONS 
 Patients with compatible epidemiological backgrounds and 
in need of immunosuppression must be tested for  T. cruzi 
infection and clinical symptoms of CD. As suggested by oth-
ers authors, 9 PCR is now a standard tool for the diagnosis and 
follow-up of such patients. Although a negative PCR cannot 
prove eradication of the parasite, a positive PCR can provide 
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early unequivocal evidence of treatment failure and could 
help drive the consideration of other therapeutic options to 
prevent acute reactivations or chronic progression of CD. 
More effective and safer drugs for the specific treatment of 
CD, particularly in its chronic stage, are urgently needed. All 
infected patients, including those immunosuppressed, would 
benefit from such drugs. Posaconazole, already in the market 
for the treatment of invasive mycoses, has an excellent safety 
profile and superior anti- T. cruzi activity compared with ben-
znidazole in experimental animal models of CD; therefore, it 
is a prime candidate for a safer and more effective treatment 
of this parasitosis. The results of the present study in an immu-
nocompromised CD patient support this notion. A successful 
clinical development of this or similar compounds like anti-
 T. cruzi drugs would enormously improve the management of 
this disease, which affects millions of people and is becoming 
an emerging global disease. 
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